Revolutionizing Vaccination Safety with Needle-Free Reconstitution TechnologyBEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province. Approved for lot release by regulatory authorities on April 15, 2025, ...

SUNNYVALE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- News Summary Fortinet®, the global cybersecurity leader driving the convergence of networking and security, today announced that FortiGuard AI-Powered Security Services and FortiCare Services have received GovRAMP, previously known as StateRAMP, authorization at a moderate impact level from the Government Risk and Authorization Management Program (GovRAMP®). "Fortinet's GovRAMP authorization underscores our commitment to delivering trusted security so ...

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- (TSX: PGIC.PR.A; PGIC) – Premium Global Income Split Corp. (the “Fund”) is pleased to announce a successful overnight treasury offering of 2,100,000 Preferred Shares and 2,100,000 Class A Shares for gross proceeds of approximately $35,175,000. The Preferred Shares and Class A Shares will continue to trade on the Toronto Stock Exchange (the “TSX”) under the existing symbols PG ...

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose re ...

Consolidated and audited report of AS Pro Kapital Grupp for the financial year 2024 will not be completed on time In the financial calendar for 2025, published on 15 November 2024, AS Pro Kapital Grupp announced that consolidated audited financial statements for the financial year 2024 will be published on 25 April 2025 at the latest. Due to the delay in auditing financial statement of one of the subsidiaries for the financial year 2024, the audit of AS Pro Kapital Grupp consolidated financial statements f ...

DUBLIN, Ga., April 23, 2025 (GLOBE NEWSWIRE) -- Morris State Bancshares, Inc. (OTCQX: MBLU) (the “Company”), the parent of Morris Bank, today announced net income of $4.9 million for the quarter ending March 31, 2025, representing an increase of $22 thousand, or 0.45%, compared to net income of $4.9 million for the quarter ended March 31, 2024. In the linked quarter comparison, net income decreased $1.2 million, or 20.04%, compared to net income of $6.1 million for the quarter ending December 31, 2024. Net ...

文章核心观点 - 临床阶段生物技术公司Silexion Therapeutics与先进交付技术和临床制造解决方案全球领导者Catalent达成战略合作，推进SIL204开发项目，有望在2026年上半年启动人体临床试验 [1][4] 合作内容 - Catalent将在法国利摩日的先进设施为Silexion的下一代siRNA候选药物SIL204进行配方开发和临床制造活动，专注优化其全身和肿瘤内递送配方，支持双路线开发策略 [2] 合作基础 - Silexion近期报告的临床前数据显示SIL204在减少原位胰腺癌模型的原发肿瘤生长和转移扩散方面有显著疗效，且可靶向多种KRAS突变 [3] 合作意义 - 此次合作是SIL204开发计划的重大进展，Catalent在复杂配方开发方面的专业知识将有助于优化SIL204配方，提升其治疗潜力 [4] 公司后续计划 - 公司计划在2025年进行额外的毒理学和药效学研究，2025年下半年向以色列卫生部提交潜在监管申请，2026年上半年向欧盟提交申请 [5] 公司简介 - Silexion Therapeutics是专注肿瘤学的临床阶段生物技术公司，开发创新RNA干扰疗法治疗KRAS突变驱动的实体瘤，其第一代产品LODER™在不可切除胰腺癌2期试验中结果良好，SIL204在临床前研究中显示出显著潜力 [6]

文章核心观点 - 临床阶段生物技术公司Silexion Therapeutics宣布与Catalent达成战略合作，推进下一代siRNA候选药物SIL204的开发，有望在2026年上半年启动人体临床试验 [1][4] 合作内容 - Catalent将在法国利摩日的先进设施为Silexion的SIL204进行配方开发和临床制造活动，专注优化其全身和瘤内递送配方，支持双路线开发策略 [2] 合作基础 - Silexion近期报告的临床前数据显示SIL204在减少原位胰腺癌模型的原发肿瘤生长和转移扩散方面有显著疗效，可靶向多种KRAS突变 [3] 合作意义 - 此次合作是SIL204开发计划的重大进展，Catalent在复杂配方开发方面的专业知识将有助于优化SIL204的配方，提升其治疗潜力 [4] 后续计划 - Silexion计划在2025年进行额外的毒理学和药效学研究，2025年下半年向以色列卫生部提交潜在监管申请，2026年上半年向欧盟提交申请 [5] 公司介绍 - Silexion是专注肿瘤学的临床阶段生物技术公司，开发创新RNA干扰疗法治疗KRAS突变驱动的实体瘤，第一代产品LODER在二期试验中显示出前景，SIL204在临床前研究中潜力显著 [6]

文章核心观点 威利斯（Willis）宣布任命哈里·默克（Harry Merker）担任北美财产与意外险（P&C）跨行业销售主管以及另类资产保险解决方案（AAIS）销售、战略与执行主管 [1] 任命信息 - 默克担任新设立的双重职位，推动威利斯P&C业务经纪增长计划，领导公司12个行业垂直领域的战略经纪销售工作与协作，负责AAIS行业垂直领域的上市战略、运营商关系、产品开发等 [2] - 默克将推动销售渠道参与、支持提案执行，与销售领导合作推广最佳实践，开展交叉销售，与精算和分析团队合作改进AAIS产品 [3] 默克背景 - 默克拥有20年商业保险和经纪经验，是经验丰富的风险管理专业人士，曾在怡安（Aon）担任多个职位 [4] 公司评价 - 公司负责人表示招聘默克是为给客户提供领先市场的成果，其战略洞察力、市场专业知识和领导力将提升为另类资产客户提供的定制解决方案 [5] 公司介绍 - 威利斯所属的WTW提供数据驱动、洞察引领的人力、风险和资本领域解决方案，借助全球视角和本地专业知识服务140个国家和市场 [5]

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Willis, a WTW business (Nasdaq: WTW), today announced the appointment of Harry Merker as Property and Casualty (P&C) Cross Industry Sales Leader and Alternative Asset Insurance Solutions (AAIS) Sales, Strategy and Execution Leader for North America (NA). In this newly created dual role, Merker will drive broking growth initiatives across Willis’ P&C business and lead strategic broking sales efforts and collaboration across the company’s 12 industry verticals. He ...